Michael Jay Ross
Independent DirectorDr. Michael Jay Ross Ph.D, also known as Mike, served as the Chairman of the Board of Ribometrix, Inc. Dr. Ross is Director of Rondo Therapeutics, Inc. from June 2024. He serves as Director of PanOptica, Inc. since 2023. He served as Director at Caraway Therapeutics, Inc. until December 2022. He serves as Director at Therini Bio, Inc. since July 08, 2019. He served as a Director of Artios Pharma Limited until 2023 and serves as Director at Eyebiotech Limited. He serves as an Independent Director of TRex Bio, Inc. since January 2020. He has been Director of Pionyr Immunotherapeutics Inc. He served as Co-Chairman at Catabasis Pharmaceuticals, Inc. (Astria Therapeutics, Inc.) from February 2016 to February 14, 2019. He was Director of Sutro Biopharma, Inc. since October 2006 until June 07, 2019. He is a Senior Partner at SV Health Investors, LLC and focuses on Therapeutics, Biotechnology and Pharmaceuticals investments and activities in the US. He served as Managing Partner at the firm since 2002. He joined SV Health Investors as a Venture Partner in 2001 and served in that role until 2002. Dr. Ross was the tenth Employee at Genentech, where he worked in roles of increasing responsibility. He served as Genentech team leader for Humulin, Roferon, Protropin and the Vice President of Drug Development during the development of Activase, Nutropin and Pulmozyme. He then started Genentech’s protein engineering and small molecule discovery effort as Vice President of Medicinal and Biomolecular Chemistry. He was a Vice President at Genentech, Inc. from 1978 to 1990. Dr. Ross served as a Director of Deciphera Pharmaceuticals, Inc since December 2015 until November 2019. Mike was also the Founding CEO of Arris Pharmaceutical whose scientists synthesized Ibruinib, MetaXen, ExSAR and CyThera (now Viacyte). He is a Board Member of Archemix Corp. He served as Director at X4 Pharmaceuticals, Inc. He was a Managing Partner in Didyma, LLC from 1999 to 2002. Dr. Ross served as a Director of Catabasis Pharmaceuticals, Inc. from April 2010 to February 14, 2019, a publicly traded biotechnology company and the Board of overseers of the Thayer School of Engineering at Dartmouth College. Dr. Ross served as a Director of Ophthotech Corp. since May 2013 until February 28, 2019. He served as Non-Employee Independent Director of Xilio Therapeutics, Inc. since February 2020 until 2023. Dr. Ross served on the boards of Cartar Proteomics, Epimmune, Genencor, MetaXen and Xenova. He received AB in Chemistry from the Dartmouth College, PhD in Chemistry from the California Institute of Technology (Caltech) and NIH Post-Doctoral Fellowship in Molecular Biology from the Harvard University. Dr. Ross had been Director of Arsanis, Inc. since February 2011.
Positions
- Company NameTRex Bio, Inc.Stock CodeTRXBPositionIndependent DirectorColleagues
